• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在德国慢性肾脏病(GCKD)研究中,明显治疗抵抗性高血压的流行情况、表型特征和预后作用。

Prevalence, phenotypic characteristics and prognostic role of apparent treatment resistant hypertension in the German Chronic Kidney Disease (GCKD) study.

机构信息

Bayer AG, Research & Early Development, Disease Understanding and Precision Biomarkers, Division Pharmaceuticals, Wuppertal, Germany.

Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg, Germany.

出版信息

J Hum Hypertens. 2023 May;37(5):345-353. doi: 10.1038/s41371-022-00701-0. Epub 2022 May 9.

DOI:10.1038/s41371-022-00701-0
PMID:35534618
Abstract

Treatment resistant hypertension (TRH) appears of particular relevance in patients with chronic kidney disease (CKD). However, causes and consequences of TRH in CKD patients remain incompletely understood. Therefore, we analyzed the prevalence of apparent TRH (aTRH), and phenotypic characteristics and prognosis associated with aTRH among participants of the German Chronic Kidney Disease (GCKD) study. As insufficient medication adherence has been shown to be a frequent cause of pseudoresistance, we also assessed treatment adherence. Study participants were classified as having aTRH, controlled hypertension and uncontrolled hypertension based on study visit blood pressure and self-reported medication intake. Drug adherence was assessed by comparing self-reported antihypertensive medication with detectable urinary drug metabolites measured by mass spectroscopy. Out of 4901 individuals included in this study, 38% were classified as having aTRH. Male sex, older age, lower estimated glomerular filtration rate (eGFR), higher body mass index (BMI), higher urine albumin-to-creatinine ratio (UACR) and presence of diabetes mellitus were independently associated with higher prevalence of aTRH in a multivariable adjusted regression model. Patients classified as aTRH had higher risk for major adverse cardiovascular events and worsening of kidney disease compared to patients with no aTRH after multivariate adjustment for potential confounders. There was a high agreement between self-reported medication and detectable urinary drug metabolites. In conclusion, in a cohort of Caucasian patients with moderately severe CKD, aTRH was highly prevalent and, in most cases, likely not caused by low medication adherence. Furthermore, aTRH was linked to cardio-renal endpoints, emphasizing the need for improved management.

摘要

治疗抵抗性高血压(TRH)在慢性肾脏病(CKD)患者中显得尤为重要。然而,CKD 患者中 TRH 的原因和后果仍不完全清楚。因此,我们分析了德国慢性肾脏病(GCKD)研究参与者中明显 TRH(aTRH)的患病率,以及与 aTRH 相关的表型特征和预后。由于药物依从性不足被认为是假性抵抗的常见原因,我们还评估了治疗依从性。研究参与者根据研究就诊时的血压和自我报告的药物摄入量被分类为 aTRH、血压控制良好和血压控制不佳。药物依从性通过比较自我报告的抗高血压药物与通过质谱法检测到的可检测尿液药物代谢物来评估。在这项研究中,共有 4901 人被纳入,其中 38%被分类为 aTRH。多变量调整回归模型显示,男性、年龄较大、估算肾小球滤过率(eGFR)较低、体重指数(BMI)较高、尿白蛋白与肌酐比值(UACR)较高以及患有糖尿病与 aTRH 患病率较高独立相关。与无 aTRH 的患者相比,经过多变量调整混杂因素后,被分类为 aTRH 的患者发生主要不良心血管事件和肾脏疾病恶化的风险更高。自我报告的药物与可检测尿液药物代谢物之间具有高度一致性。总之,在一组高加索裔中重度 CKD 患者中,aTRH 患病率很高,在大多数情况下,不太可能是由于药物依从性低引起的。此外,aTRH 与心脏肾脏终点相关,强调需要改善管理。

相似文献

1
Prevalence, phenotypic characteristics and prognostic role of apparent treatment resistant hypertension in the German Chronic Kidney Disease (GCKD) study.在德国慢性肾脏病(GCKD)研究中,明显治疗抵抗性高血压的流行情况、表型特征和预后作用。
J Hum Hypertens. 2023 May;37(5):345-353. doi: 10.1038/s41371-022-00701-0. Epub 2022 May 9.
2
Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.慢性肾脏病中貌似治疗抵抗性高血压的患病率及预后意义:慢性肾功能不全队列研究报告
Hypertension. 2016 Feb;67(2):387-96. doi: 10.1161/HYPERTENSIONAHA.115.06487. Epub 2015 Dec 28.
3
Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus.2 型糖尿病患者的耐药性高血压、时间更新的血压值与肾脏结局。
J Am Heart Assoc. 2017 Sep 22;6(9):e006745. doi: 10.1161/JAHA.117.006745.
4
Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.明显治疗抵抗性高血压的患病率及其对慢性肾脏病患者预后的影响
Hypertension. 2015 Nov;66(5):998-1005. doi: 10.1161/HYPERTENSIONAHA.115.05694. Epub 2015 Sep 8.
5
Chronic kidney disease and incident apparent treatment-resistant hypertension among blacks: Data from the Jackson Heart Study.黑人中的慢性肾脏病与初发明显难治性高血压:来自杰克逊心脏研究的数据。
J Clin Hypertens (Greenwich). 2017 Nov;19(11):1117-1124. doi: 10.1111/jch.13065. Epub 2017 Sep 17.
6
Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease.慢性肾脏病患者的炎症与貌似治疗抵抗性高血压
Hypertension. 2019 Apr;73(4):785-793. doi: 10.1161/HYPERTENSIONAHA.118.12358.
7
Current antihypertensive treatment and treatment-resistant hypertension in Japanese patients with chronic kidney disease.日本慢性肾脏病患者的当前抗高血压治疗及难治性高血压
Clin Exp Nephrol. 2022 Nov;26(11):1100-1110. doi: 10.1007/s10157-022-02250-9. Epub 2022 Aug 4.
8
Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).抗高血压和降脂治疗预防心脏病发作试验(ALLHAT):治疗抵抗性高血压与心血管疾病和终末期肾病的发病率。
Hypertension. 2014 Nov;64(5):1012-21. doi: 10.1161/HYPERTENSIONAHA.114.03850. Epub 2014 Aug 4.
9
Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes.2型糖尿病患者中貌似难治性高血压、血压控制与慢性肾脏病进展
Kidney Blood Press Res. 2018;43(2):422-438. doi: 10.1159/000488255. Epub 2018 Mar 16.
10
Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care.心血管疾病患者中貌似难治性高血压的患病率及临床特征:一项二级医疗中的横断面队列研究
BMJ Open. 2017 Sep 6;7(9):e016692. doi: 10.1136/bmjopen-2017-016692.

引用本文的文献

1
Correlational Analysis of Resistant Hypertension with Diabetes Mellitus, Chronic Kidney Disease, and the Interplay of Sodium, Calcium, Magnesium, and Phosphorus.顽固性高血压与糖尿病、慢性肾脏病以及钠、钙、镁和磷相互作用的相关性分析
Vasc Health Risk Manag. 2025 Apr 7;21:217-228. doi: 10.2147/VHRM.S504454. eCollection 2025.
2
Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease.醛固酮靶向治疗:在顽固性高血压和慢性肾脏病中的早期应用
Eur Heart J. 2025 Jul 14;46(27):2618-2642. doi: 10.1093/eurheartj/ehaf225.
3
Apparent Treatment-Resistant Hypertension in the First Year Associated With Cardiovascular Mortality in Peritoneal Dialysis Patients.

本文引用的文献

1
Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study.心血管健康与血压控制达标到血压明显难治的转变:杰克逊心脏研究和 REGARDS 研究。
Hypertension. 2020 Dec;76(6):1953-1961. doi: 10.1161/HYPERTENSIONAHA.120.15890. Epub 2020 Nov 2.
2
2020 International Society of Hypertension Global Hypertension Practice Guidelines.2020年国际高血压学会全球高血压实践指南
Hypertension. 2020 Jun;75(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. Epub 2020 May 6.
3
Genetic studies of urinary metabolites illuminate mechanisms of detoxification and excretion in humans.
腹膜透析患者第一年表现出的治疗抵抗性高血压与心血管死亡率相关。
Am J Hypertens. 2024 Jun 14;37(7):514-522. doi: 10.1093/ajh/hpae010.
遗传研究尿液代谢物阐明了人类解毒和排泄的机制。
Nat Genet. 2020 Feb;52(2):167-176. doi: 10.1038/s41588-019-0567-8. Epub 2020 Jan 20.
4
Prevalence of Apparent Treatment-Resistant Hypertension in the United States.美国显性治疗抵抗性高血压的流行情况。
Hypertension. 2019 Feb;73(2):424-431. doi: 10.1161/HYPERTENSIONAHA.118.12191.
5
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.耐药性高血压:检测、评估与管理:美国心脏协会科学声明。
Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.
6
Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease.慢性肾脏病患者的血压模式与靶器官损害。
Hypertension. 2018 Oct;72(4):929-936. doi: 10.1161/HYPERTENSIONAHA.118.11608.
7
Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study.慢性肾脏病中的血压控制:来自德国慢性肾脏病(GCKD)研究的横断面分析。
PLoS One. 2018 Aug 20;13(8):e0202604. doi: 10.1371/journal.pone.0202604. eCollection 2018.
8
Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes.2型糖尿病患者中貌似难治性高血压、血压控制与慢性肾脏病进展
Kidney Blood Press Res. 2018;43(2):422-438. doi: 10.1159/000488255. Epub 2018 Mar 16.
9
Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease.显性血管疾病患者中明显的抗高血压治疗和血管事件及死亡率风险。
J Hypertens. 2018 Jan;36(1):143-150. doi: 10.1097/HJH.0000000000001494.
10
Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation.接受肾去神经支配治疗的顽固性高血压患者对抗高血压药物的依从性
J Am Heart Assoc. 2016 Feb 12;5(2):e002343. doi: 10.1161/JAHA.115.002343.